Hugel (145020) Q1 2025 earnings summary

Executive summary

• Revenue for 1Q25 reached KRW 89.8bn, up 20.9% year-over-year from 1Q24.

• Net income for 1Q25 was KRW 30.9bn, a 35.9% increase compared to 1Q24.

• Operating profit rose to KRW 39.0bn, up 62.6% year-over-year.

• The company specializes in botulinum toxin, HA fillers, medical devices, and cosmetics, with a diversified portfolio and strong international presence.

• Operates through 12 consolidated subsidiaries, with significant R&D and regulatory achievements, including FDA and NMPA approvals.

Financial highlights

• Gross profit for 1Q25 was KRW 69.0bn, with a gross margin of 76.8%, unchanged from 1Q24.

• SG&A expenses decreased 9.3% year-over-year to KRW 30.1bn.

• Pre-tax income increased 39.7% year-over-year to KRW 41.1bn.

• Basic EPS: KRW 2,701 (Q1 2025) vs. KRW 1,923 (Q1 2024).

• Cash and cash equivalents: KRW 163.97 billion as of March 31, 2025.

Segment performance

• Botulinum Toxin revenue grew 18.8% year-over-year to KRW 40.7bn.

• Dermal Filler revenue increased 17.7% year-over-year to KRW 34.4bn.

• Cosmetics revenue rose 39.3% year-over-year to KRW 13.2bn.

• Thread product revenue increased 13.2% year-over-year to KRW 1.5bn.

• International sales of Botulinum Toxin & Dermal Filler grew 21.1% year-over-year to KRW 48.5bn.